DSS (DSS) investor relations material

Executive summary

• Operates four business lines: Product Packaging, Biotechnology, Commercial Lending, and Securities & Investment Management, with global reach and diversified operations.

• Revenue for the quarter and six months ended June 30, 2026, declined 32% and 22% year-over-year, respectively, due to lower customer orders, delayed onboarding of new customers, and asset sales.

• Net loss increased to $11.3 million for the six months ended June 30, 2026, up 43% from the prior year, driven by revenue declines and higher stock-based compensation.

Financial highlights

• Total revenue for Q2 2026 was $3.6 million, down from $5.3 million in Q2 2025; six-month revenue was $7.9 million, down from $10.2 million.

• Net loss for Q2 2026 was $5.0 million, compared to $2.6 million in Q2 2025; six-month net loss was $11.3 million, compared to $7.9 million in 2025.

• Gross margin declined due to lower sales and higher costs in certain segments.

• Cash and cash equivalents at June 30, 2026, were $4.1 million, with $2.8 million in marketable securities.

• Negative working capital of $39.9 million as of June 30, 2026.

Outlook and guidance

• Management expects onboarding of new customers in the second half of 2026 to improve revenue.

• Plans to pursue additional liquidity through asset sales, financing, and cost reductions, but substantial doubt remains about the ability to continue as a going concern.